INDICATIONS     CONTRA-INDICATIONS     DOSAGE     SIDE-EFFECTS     PREGNANCY     OVERDOSE     IDENTIFICATION     PATIENT INFORMATION

Logo MYCOSTATIN ORAL TABLETS

SCHEDULING STATUS:
S4

PP ZIMBABWE ONLY

PROPRIETARY NAME
(and dosage form):

MYCOSTATIN ORAL TABLETS

COMPOSITION
MYCOSTATIN ORAL TABLETS each contain 500 000 units
nystatin.

PHARMACOLOGICAL CLASSIFICATION
Category A 20.1.7 Antifungal antibiotics.

PHARMACOLOGICAL ACTION
Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool.
Nystatin is an antibiotic with antifungal activity against a wide variety of yeasts and yeast-like fungi. The antifungal activity of nystatin is at least in part dependent on its binding to a sterol moiety, primarily ergosterol, present in the membrane of sensitive fungi, which results in an increase in the permeability of the membrane and leakage of intra-cellular components.
Nystatin exhibits no appreciable activity against bacteria, protozoa or viruses.

INDICATIONS
MYCOSTATIN ORAL TABLETS are indicated for the treatment of intestinal candidiasis.

CONTRA-INDICATIONS
Patients with a history of hypersensitivity to any component.

Pregnancy and Lactation
Safety of use during pregnancy has not been established. It is not known whether nystatin is excreted in human milk.

DOSAGE AND DIRECTIONS FOR USE
The usual dose is one tablet (500 000 units) three times daily. This dosage may be increased to two tablets (1 000 000 units) three times daily if intestinal fungi are not adequately suppressed. The treatment should generally be continued for at least 48 hours after clinical cure to prevent relapse.

SIDE EFFECTS AND SPECIAL PRECAUTIONS
Nystatin may produce diarrhoea and gastro-intestinal disturbance, nausea and vomiting. Rash, including urticaria, has been reported. Stevens-Johnson syndrome has been reported very rarely.
MYCOSTATIN ORAL TABLETS should not be used for the treatment of systemic mycoses.
If irritation or sensitization develops, treatment should be discontinued.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT
Treatment of overdosage should be symptomatic and supportive.

IDENTIFICATION
Round, biconvex, chocolate coloured tablets.

PRESENTATION
Bottles of 20 and 100 tablets.

STORAGE INSTRUCTIONS
Store at room temperature not exceeding 25°C.
KEEP OUT OF REACH OF CHILDREN.

REFERENCE NUMBER
A 155 (Act 101 of 1965).

NAME AND BUSINESS ADDRESS OF APPLICANT
BRISTOL-MYERS SQUIBB (PTY) LTD*
47 Van Buuren Road
BEDFORDVIEW 2008.

DATE OF PUBLICATION OF THIS PACKAGE INSERT
April 1993

*Authorised user of the TM MYCOSTATIN.

2900671

Updated on this site: June 2005
Source: Pharmaceutical Industry

SAEPI HOME PAGE      TRADE NAME INDEX      GENERIC NAME INDEX      FEEDBACK
Information presented by Malahyde Information Systems © Copyright 1996-2005